"Dopamine Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
| Descriptor ID |
D015259
|
| MeSH Number(s) |
D27.505.519.625.150 D27.505.696.577.150
|
| Concept/Terms |
Dopamine Agents- Dopamine Agents
- Agents, Dopamine
- Dopaminergic Agents
- Agents, Dopaminergic
- Dopaminergic Drugs
- Drugs, Dopaminergic
- Dopamine Drugs
- Drugs, Dopamine
Dopamine Effect- Dopamine Effect
- Effect, Dopamine
- Dopaminergic Effect
- Effect, Dopaminergic
- Dopaminergic Effects
- Effects, Dopaminergic
- Dopamine Effects
- Effects, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agents".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agents".
This graph shows the total number of publications written about "Dopamine Agents" by people in this website by year, and whether "Dopamine Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Agents" by people in Profiles.
-
Memantine treatment of trichotillomania. Ann Clin Psychiatry. 2020 05 01; 32(2):144-145.
-
Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
-
Operant responding for optogenetic excitation of LDTg inputs to the VTA requires D1 and D2 dopamine receptor activation in the NAcc. Behav Brain Res. 2017 08 30; 333:161-170.
-
Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling. Cereb Cortex. 2017 01 01; 27(1):435-446.
-
The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol. 2016 Dec; 263(12):2419-2423.
-
Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder. J Subst Abuse Treat. 2017 01; 72:32-39.
-
Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making. J Neurosci. 2016 06 22; 36(25):6732-41.
-
The role of neuroplasticity in dopaminergic therapy for Parkinson disease. Nat Rev Neurol. 2013 May; 9(5):248-56.
-
s Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacol Rep. 2013; 65(2):343-9.
-
Previous exposure to nicotine enhances the incentive motivational effects of amphetamine via nicotine-associated contextual stimuli. Neuropsychopharmacology. 2012 Sep; 37(10):2277-84.